Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC7731 | SX 011 |
| Potent p38α inhibitor (IC50 = 9 nM). Also inhibits p38β and JNK-2 (IC50 values are 90 nM and 100 nM respectively). Displays no significant activity at p38γ, p38δ, ERK-2 and JNK-1. | |
| BCC7732 | A 987306 |
| Potent histamine H4 receptor antagonist (pKi values are 8.24 and 8.47 in human and rat H4 receptors respectively). Displays 162-fold, 620-fold, and > 1600-fold selectivity over human H3, H1 and H2 receptors. Blocks zymosan-induced neutrophil reflux and attenuates thermal hypersensitivity in vivo (ED50 = 42 μmol/kg, ip). | |
| BCC7733 | Src I1 |
| Potent, competitive dual site (ATP- and peptide-binding) Src kinase inhibitor (IC50 values are 44 and 88 nM for Src and Lck respectively). Inhibits VEGFR2 and c-fms at higher concentrations (IC50 values are 0.32 and 30 μM respectively). Can be used in parallel with PP 1 and PP 2 to inhibit Src family kinases. | |
| BCC7734 | FR 171113 |
| Protease-activated receptor 1 (PAR1) antagonist. Exhibits potent antiplatelet activity in vitro; inhibits thrombin TRAP-6-induced platelet aggregation (IC50 = 2.5 μM) with no effect on coagulation time. | |
| BCC7740 | BMS 195614 |
| Neutral retinoic acid receptor (RAR) α-selective antagonist (Ki = 2.5 nM). Displays no significant effect on nuclear receptor corepressor (NCoR) binding; moderately decreases SMRT binding to RAR. Antagonizes agonist-induced coactivator (CoA) recruitment. | |
| BCC7741 | GSK 4112 |
| Selective Rev-Erbα agonist (EC50 = 250 nM). Enhances recruitment of nuclear receptor co-repressor (NCoR) peptide to Rev-Erbα; causes acute suppression of Bmal1 gene transcription. Induces phase shifts in the circadian clock. | |
| BCC7745 | TMCB |
| Dual-kinase inhibitor; inhibits both casein kinase 2 (CK2) and extracellular-signal-regulated kinase 8 (ERK8) (IC50 = 0.50 μM for both CK2 and ERK8). Displays selectivity for CK2 over protein kinases normally susceptible to CK2 inhibitors (Ki values are 0.25, 8.65, 11.90 and 15.25 μM for CK2, PIM1, DYRK1a and HIPK2 respectively). | |
| BCC7748 | DS2 |
| Positive allosteric modulator of δ-subunit containing GABAA receptors (EC50 = 142 nM for α4β3δ receptors). Displays no effects on GABA responses mediated by α4β3γ2 and α1β3γ2 receptors. | |
